Mar 22, 2024
- Mar 21, 2025

The New Era of Biosimilar Therapeutics for Multiple Sclerosis

EARNed Credits


AMA PRA Category 1 CreditTM



This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, led by Dr. Jiwon Oh, will first provide an overview of biosimilar development, including an explanation of the steps for a proposed biosimilar antibody. Following, recent clinical trial data in the biosimilar treatment landscape will be reviewed, including drugs in the pipeline, along with clinical implications for patients with multiple sclerosis. Dr. Oh will conclude with a summary of biosimilars therapeutics in 2024, assessing the potential impact on improving outcomes for patients with multiple sclerosis.

Who Should Attend

MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis

Provided By

Course Faculty

Jiwon Oh, MD, PhD
St. Michael’s Hospital University of Toronto Toronto, Ontario, Canada

Learning Objectives


Review the science of biologic development and approval process for biosimilar therapeutics, as well as lessons learned from approved biosimilars in other therapeutic areas


Analyze the safety and efficacy data for biosimilar treatments to update their individualized treatment plans for patients with relapsing MS

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Jiwon Oh, MD, PhD Consultant/Advisor: Biogen-Idec; EMD Serono; F. Hoffmann-La Roche Ltd; Horizon Therapeutics plc; Lilly; Novartis AG; Sandoz; Sanofi

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.

Learners should only claim credit commensurate with the extent of their participation.

This activity has been supported by an independent educational grant from Sandoz.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sandoz do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact [email protected].

Mar 22, 2024
- Mar 21, 2025

The New Era of Biosimilar Therapeutics for Multiple Sclerosis

Related Webcast Courses

Differentiating S1P-Based Therapeutics for the Treatment of Patients with Multiple Scleros...
Review of New and Emerging Therapies that Improve Tolerability and Adherence in Patients w...
Brain Penetrant BTK Update: Reducing Neuroinflammation to Optimize Outcomes for Patients w...